Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-17-0330 ◽

2017 ◽

Vol 17 (1) ◽

pp. 215-221 ◽

Author(s):

Elaine T. Lam ◽

S. Gail Eckhardt ◽

Wells Messersmith ◽

Antonio Jimeno ◽

Cindy L. O'Bryant ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Advanced Solid Tumors ◽

Humanized Monoclonal Antibody ◽

Antibody Targeting

Download Full-text

A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.3537 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 3537-3537 ◽

Author(s):

M. N. Saleh ◽

I. Percent ◽

T. E. Wood ◽

J. Posey ◽

J. Shah ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Death Receptor ◽

Advanced Solid Tumors ◽

Death Receptor 5 ◽

Humanized Monoclonal Antibody ◽

Antibody Targeting

Download Full-text

A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors

Investigational New Drugs ◽

10.1007/s10637-018-0713-7 ◽

2019 ◽

Vol 37 (5) ◽

pp. 1061-1074 ◽

Author(s):

Toshihiko Doi ◽

Takeshi Aramaki ◽

Hirofumi Yasui ◽

Kei Muro ◽

Masafumi Ikeda ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Japanese Patients ◽

Humanized Monoclonal Antibody ◽

Antibody Targeting

Download Full-text

A phase I study of sonepcizumab (S), a humanized monoclonal antibody to sphingosine-1-phosphate (S1P), in patients with advanced solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.2560 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 2560-2560 ◽

Author(s):

M. S. Gordon ◽

R. Just ◽

L. S. Rosen ◽

A. Dorr

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Advanced Solid Tumors ◽

Humanized Monoclonal Antibody ◽

Sphingosine 1 Phosphate

Download Full-text

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors

Annals of Oncology ◽

10.1093/annonc/mds511 ◽

2013 ◽

Vol 24 (3) ◽

pp. 784-791 ◽

Author(s):

V.M. Macaulay ◽

M.R. Middleton ◽

A.S. Protheroe ◽

A. Tolcher ◽

V. Dieras ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Advanced Solid Tumors ◽

Insulin Like Growth Factor ◽

Humanized Monoclonal Antibody

Download Full-text

404 Phase I study of MEDI-575, a fully human monoclonal antibody targeting PDGFR-alpha in subjects with advanced solid tumors

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(10)72111-x ◽

2010 ◽

Vol 8 (7) ◽

pp. 128 ◽

Author(s):

R. Lechleider ◽

C. Becerra ◽

M. Liang ◽

R. Narwal ◽

L. Shi ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Human Monoclonal Antibody ◽

Advanced Solid Tumors ◽

Antibody Targeting ◽

Download Full-text

Phase I Study of U3-1287, A Human Monoclonal Antibody Targeting Her3, in Japanese Patients with Advanced Solid Tumors

Annals of Oncology ◽

10.1016/s0923-7534(20)33026-x ◽

2012 ◽

Vol 23 ◽

pp. ix161-ix162

Author(s):

H. Wakui ◽

N. Yamamoto ◽

S. Nakamichi ◽

Y. Tamura ◽

H. Nokihara ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Human Monoclonal Antibody ◽

Japanese Patients ◽

Advanced Solid Tumors ◽

Antibody Targeting

Download Full-text

Abstract C18: A phase I study of enavatuzumab (PDL192, ABT-361), a first-in-class human monoclonal antibody targeting TWEAK (tumor necrosis factor-like inducer of apoptosis) receptor, in patients (Pts) with advanced solid tumors.

10.1158/1535-7163.targ-11-c18 ◽

2011 ◽

Author(s):

Elaine T. Lam ◽

S. Gail Eckhardt ◽

Wells Messersmith ◽

Antonio Jimeno ◽

Cindy L. O'Bryant ◽

...

Keyword(s):

Monoclonal Antibody ◽

Tumor Necrosis Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Tumor Necrosis ◽

Human Monoclonal Antibody ◽

Advanced Solid Tumors ◽

Antibody Targeting ◽

Necrosis Factor

Download Full-text

Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors

Annals of Oncology ◽

10.1093/annonc/mdv144 ◽

2015 ◽

Vol 26 (6) ◽

pp. 1230-1237 ◽

Author(s):

E.G. Chiorean ◽

H.I. Hurwitz ◽

R.B. Cohen ◽

J.D. Schwartz ◽

R.P. Dalal ◽

...

Keyword(s):

Monoclonal Antibody ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Advanced Solid Tumors ◽

Endothelial Growth Factor

Download Full-text

Abstract CT014: Initial results from the Phase I study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors

10.1158/1538-7445.am2019-ct014 ◽

2019 ◽

Author(s):

Alison Schram ◽

Anna Spreafico ◽

Marc Oliva ◽

Irene Brana ◽

Elena Garralda ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Advanced Solid Tumors ◽

Initial Results

Download Full-text

A first-in-human phase I study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously every three weeks in patients with advanced solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.3014 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 3014-3014 ◽

Author(s):

C. D. Weekes ◽

P. Hegde ◽

Y. Xin ◽

R. Yu ◽

H. Xiang ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Human Monoclonal Antibody ◽

Advanced Solid Tumors

Download Full-text